6
ADVERTISEMENT FEATURE COVER STORY: EXPAC
‘Expac Vision 28-60’: the road to £60 million
The Expac group, comprising Expac (Preston) Ltd and Expac (Commercial) Ltd, has built a formidable reputation as a British formulator, contract manufacturer and packer serving the personal care, household, and pet care markets. Established in 1980, the business has decades of experience in formulation, manufacturing, packaging, and customer support. Investment since joining Dr Graham Royle’s GRI Group in 2016 has transformed its scale and capabilities. Now, the ambition is bigger, much bigger. ‘Vision 28-60’ is Expac’s strategic growth
initiative: a plan to reach £60 million ($81 million) in group turnover by 2028. With the group currently generating around £30 million, the objective is to double the size of the business through organic sales growth, strategic investment, operational excellence, and selected acquisitions, which are underway.
‘Vision 28-60’ is not a departure from what Expac is. It is an acceleration of it.
Building from a position of strength Expac has already demonstrated that investment, expertise, and ambition can translate into significant growth. Following its acquisition by GRI Group in 2016,
the company invested substantially in people, equipment, technology, and infrastructure. By 2025, turnover had increased sixfold since its 2016 level, while more than £7 million had been invested in new plant, machinery, and laboratory technologies. Today, Expac’s flagship manufacturing
operations in Leyland includes 83,000 sq ft of facilities across two sites, with extensive liquid, creams and powder manufacturing and filling capabilities. It includes hot and cold liquid mixing vessels, multiple liquid filling lines, and dedicated powder facilities. Modern contract manufacturing, however, is
not simply about capacity. Customers increasingly need partners capable of managing different formulations, pack formats, production volumes, regulatory requirements, and speed-to-market expectations. Expac has built its proposition around that complexity.
Technical expertise at the heart of the proposition At the centre of Expac’s offering is its technical capability in both process and product innovation. The company’s in-house Product
Development team collaborates with customers from initial brief through to formulation sign- off, combining formulation science, consumer requirements, and product performance. This science-led approach allows Expac to operate
PERSONAL CARE MAGAZINE October 2026
Dr Graham Royle FIOD, Chairman and CEO of GRI Group, whose ‘Vision 28-60’ initiative is shaping the next phase of Expac’s growth
PERSONAL
Substantiating performance of menopausal skin care
The tolerogen: restoring tolerance in urban skin
OCTOBER 2026 VOL 27 ISSUE 9
lotions, gels, balms, oils, waxes, powders, salts and alcohol-based fragrances across personal care, household, and pet care applications. That breadth gives ‘Vision 28-60’ an important
advantage as Expac is not dependent on any sole product category or manufacturing technology. It has multiple routes to growth.
A manufacturing platform designed for flexibility Expac operates multiple blending and filling production lines, from small-volume formats to larger-scale production. Filling operations accommodate bottles, tubes, jars, tubs, pouches, and other formats, with dedicated areas for powders and fragrances. Dedicated powder facilities include blending
A VISION FOR GROWTH
Science-led approach to advanced personal care contract manufacturing
further upstream than a traditional manufacturing partner. A customer can approach the business with an idea, specification, market requirement, or existing formulation, and Expac can support the subsequent development process. This can include formulation development, testing, packaging, artwork, and project management before manufacturing. The breadth of product expertise is equally significant. Expac manufactures liquids, creams,
vessels and filling equipment capable of handling talc, salts, starches, granules, and flakes. For customers, this flexibility can make the
difference between a manufacturer that simply produces a specification and a partner that helps solve a problem. For Expac, it provides a platform for future growth.
Organic and acquisitive growth ‘Vision 28-60’ has two fundamental growth engines: organic and acquisition. Organic growth will come from expanding
customer relationships, winning new business and increasing the services and products provided. Expac also seeks opportunities for new products, ranges, and manufacturing services, supported by its in-house product development expertise. This creates an opportunity to become a
broader manufacturing partner. Acquisitions provides the second and
transformational route - and that strategy has already begun. On 30 January 2026, Expac completed the
acquisition of the trade, assets, and intellectual property of the former MPM Consumer Products business. The transaction added a 75,000 sq ft manufacturing facility in Manchester, 6 additional blending vessels, 24 filling lines, more than 40 million units of additional annual capacity, further warehousing and another fully equipped NPD laboratory. It also brought 75 experienced employees into the wider Expac operation. This is precisely the type of strategic move that
gives ‘Vision 28-60’ impetus. This acquisition does not simply add revenue. It adds customers, people, equipment, expertise, intellectual property, capacity, and new routes to market. Dr Graham Royle is already in due diligence on
another exciting manufacturing business that will join the Expac group. Completion is expected in January 2027. Watch this space!
www.personalcaremagazine.com
PREVIEW
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95 |
Page 96 |
Page 97 |
Page 98 |
Page 99 |
Page 100 |
Page 101 |
Page 102 |
Page 103 |
Page 104 |
Page 105 |
Page 106 |
Page 107 |
Page 108 |
Page 109 |
Page 110 |
Page 111 |
Page 112 |
Page 113 |
Page 114 |
Page 115 |
Page 116 |
Page 117 |
Page 118 |
Page 119 |
Page 120 |
Page 121 |
Page 122 |
Page 123 |
Page 124 |
Page 125 |
Page 126 |
Page 127 |
Page 128 |
Page 129 |
Page 130 |
Page 131 |
Page 132
